- In May 2024, NovaResp Technologies secured USD 3 million in a seed extension round to support clinical trials for its cMAP positive airway pressure software. This funding will accelerate the development of their innovative solution aimed at improving sleep apnea treatment
- In February 2024, EnsoData obtained FDA approval for its AI-based EnsoSleep algorithm, designed for diagnosing sleep disorders. This approval enhances the capabilities of EnsoSleep in providing accurate and efficient sleep disorder assessments using artificial intelligence
- In February 2024, Mount Sinai researchers secured USD 4 million in funding to develop and study AI-powered models that predict adverse outcomes in obstructive sleep apnea. This initiative aims to improve patient care by leveraging advanced AI technologies for better diagnosis and risk assessment
- In November 2023, Vivos Therapeutics received FDA 510(k) clearance for its CARE (Complete Airway Repositioning and/or Expansion) oral devices, designed for adults with severe obstructive sleep apnea (OSA). This approval includes the company's key DNA, mRNA, and mmRNA oral appliances, marking a significant milestone in expanding treatment options for OSA patients
- In October 2023, ResMed partnered with Bittium Biosignals Ltd, a subsidiary of Bittium Corporation, to distribute Bittium Respiro, an advanced home sleep apnea test and analysis solution. The agreement includes the Respiro measuring device, accessories, and the Respiro Analyst software platform, covering countries like Norway, the UK, Switzerland, Ireland, Finland, and Sweden. This non-exclusive deal enhances ResMed's portfolio in the sleep apnea market
Frequently Asked Questions
The market is segmented based on Segmentation, By Diseases Type (Obstructive Sleep Apnea Syndrome, Central Sleep Apnea Syndrome, and Complex Sleep Apnea Syndrome), Type (Devices and Therapy), Patient Demographics (Pediatric, Adult, and Geriatric), End-User (Hospital/ Clinics, Diagnostic Centers, Ambulatory Care Centers, Specialty Care Centers, and Home Healthcare), Distribution Channel (Direct Tender and Retail Sales) – Industry Trends and Forecast to 2031
.
The Global Sleep Apnea Devices Market size was valued at USD 4.44 USD Billion in 2023.
The Global Sleep Apnea Devices Market is projected to grow at a CAGR of 7.7% during the forecast period of 2024 to 2031.
The major players operating in the market include - NIHON KOHDEN CORPORATION - Koninklijke Philips N.V. - GENERAL ELECTRIC COMPANY - Siemens Healthcare Private Limited - Natus Medical ,orporated - Compumedics Limited, etc..
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
